Funding

NovaGo Therapeutics

Switzerland · Biotech

NovaGo Therapeutics is a clinical-stage biotech developing anti-Nogo-A antibodies intended to promote nerve regeneration and functional recovery after central nervous system injury.

Visit novagotherapeutics.comFunding history

Product

Its lead anti-Nogo-A antibody targets a protein that inhibits nerve-fibre regeneration and neuroplasticity. The intended treatment seeks to improve functional recovery; the lead program is moving toward a 120-patient proof-of-concept study in acute spinal-cord injury.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series BCHF 24MNeurimmune — LeadPureos Bioventures — Lead

Investors

NeurimmuneLed Series BPureos BioventuresLed Series B

Coverage

Sep 2, 2026NovaGo Therapeutics · Series B

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesnovagotherapeutics.com ↗